RxDoctor Payments Data

Angela Greene

Psychiatric/Mental Health · Flowood, MSNPI 1467971416

Payments from drug & device makers

$913in general payments, 2019–2025

Across 50 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$382
  • Alkermes, Inc.$115
  • Axsome Therapeutics, Inc.$76
  • Vanda Pharmaceuticals Inc.$64
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$47
  • Takeda Pharmaceuticals U.S.A., Inc.$45
  • plus $185 from 7 others

What the payments were for

  • Food & beverage$86695%
  • Education$475%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$913 in reported general payments places this provider in the 55th percentile of 486 psychiatric/mental health providers in Mississippi.

See all psychiatric/mental health providers in Mississippi

Medicare billing

Part B allowed, 2024
$15,196
Medicare patients
63
Services billed
229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate13$45,585
AristadaAripiprazole Lauroxil13$45,501
VraylarCariprazine Hcl12$17,536
TrintellixVortioxetine Hydrobromide22$10,149
BelsomraSuvorexant12$6,894
Olanzapine52$1,694
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine43$1,419
Bupropion XlBupropion Hcl81$1,119
Alprazolam117$1,072
Venlafaxine Hcl ErVenlafaxine Hcl69$1,029
Mirtazapine54$969
Duloxetine Hcl60$895
Clonazepam96$773
Aripiprazole41$737
Oxcarbazepine28$733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Aristada$115$45,50113 claims
AbbVieVraylar$382$17,53612 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$45$10,14922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 486 psychiatric/mental health providers in Mississippi.

Other psychiatric/mental health in Flowood

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →